Cargando…

Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study

BACKGROUND: The receptor for advanced glycation end products (RAGE) is a multiligand signal transduction receptor that can initiate and perpetuate inflammation. Its soluble isoform (sRAGE) acts as a decoy receptor for RAGE ligands, and is thought to afford protection against inflammation. With the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Miniati, Massimo, Monti, Simonetta, Basta, Giuseppina, Cocci, Franca, Fornai, Edo, Bottai, Matteo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072955/
https://www.ncbi.nlm.nih.gov/pubmed/21450080
http://dx.doi.org/10.1186/1465-9921-12-37
_version_ 1782201597370040320
author Miniati, Massimo
Monti, Simonetta
Basta, Giuseppina
Cocci, Franca
Fornai, Edo
Bottai, Matteo
author_facet Miniati, Massimo
Monti, Simonetta
Basta, Giuseppina
Cocci, Franca
Fornai, Edo
Bottai, Matteo
author_sort Miniati, Massimo
collection PubMed
description BACKGROUND: The receptor for advanced glycation end products (RAGE) is a multiligand signal transduction receptor that can initiate and perpetuate inflammation. Its soluble isoform (sRAGE) acts as a decoy receptor for RAGE ligands, and is thought to afford protection against inflammation. With the present study, we aimed at determining whether circulating sRAGE is correlated with emphysema and chronic cor pulmonale in chronic obstructive pulmonary disease (COPD). METHODS: In 200 COPD patients and 201 age- and sex-matched controls, we measured lung function by spirometry, and sRAGE by ELISA method. We also measured the plasma levels of two RAGE ligands, N-epsilon-carboxymethyl lysine and S100A12, by ELISA method. In the COPD patients, we assessed the prevalence and severity of emphysema by computed tomography (CT), and the prevalence of chronic cor pulmonale by echocardiography. Multiple quantile regression was used to assess the effects of emphysema, chronic cor pulmonale, smoking history, and comorbid conditions on the three quartiles of sRAGE. RESULTS: sRAGE was significantly lower (p = 0.007) in COPD patients (median 652 pg/mL, interquartile range 484 to 1076 pg/mL) than in controls (median 869 pg/mL, interquartile range 601 to 1240 pg/mL), and was correlated with the severity of emphysema (p < 0.001), the lower the level of sRAGE the greater the degree of emphysema on CT. The relationship remained statistically significant after adjusting for smoking history and comorbid conditions. In addition, sRAGE was significantly lower in COPD patients with chronic cor pulmonale than in those without (p = 0.002). Such difference remained statistically significant after adjusting for smoking history, comorbidities, and emphysema severity. There was no significant difference in the plasma levels of the two RAGE ligands between cases and controls. CONCLUSIONS: sRAGE is significantly lower in patients with COPD than in age- and sex-matched individuals without airflow obstruction. Emphysema and chronic cor pulmonale are independent predictors of reduced sRAGE in COPD.
format Text
id pubmed-3072955
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30729552011-04-09 Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study Miniati, Massimo Monti, Simonetta Basta, Giuseppina Cocci, Franca Fornai, Edo Bottai, Matteo Respir Res Research BACKGROUND: The receptor for advanced glycation end products (RAGE) is a multiligand signal transduction receptor that can initiate and perpetuate inflammation. Its soluble isoform (sRAGE) acts as a decoy receptor for RAGE ligands, and is thought to afford protection against inflammation. With the present study, we aimed at determining whether circulating sRAGE is correlated with emphysema and chronic cor pulmonale in chronic obstructive pulmonary disease (COPD). METHODS: In 200 COPD patients and 201 age- and sex-matched controls, we measured lung function by spirometry, and sRAGE by ELISA method. We also measured the plasma levels of two RAGE ligands, N-epsilon-carboxymethyl lysine and S100A12, by ELISA method. In the COPD patients, we assessed the prevalence and severity of emphysema by computed tomography (CT), and the prevalence of chronic cor pulmonale by echocardiography. Multiple quantile regression was used to assess the effects of emphysema, chronic cor pulmonale, smoking history, and comorbid conditions on the three quartiles of sRAGE. RESULTS: sRAGE was significantly lower (p = 0.007) in COPD patients (median 652 pg/mL, interquartile range 484 to 1076 pg/mL) than in controls (median 869 pg/mL, interquartile range 601 to 1240 pg/mL), and was correlated with the severity of emphysema (p < 0.001), the lower the level of sRAGE the greater the degree of emphysema on CT. The relationship remained statistically significant after adjusting for smoking history and comorbid conditions. In addition, sRAGE was significantly lower in COPD patients with chronic cor pulmonale than in those without (p = 0.002). Such difference remained statistically significant after adjusting for smoking history, comorbidities, and emphysema severity. There was no significant difference in the plasma levels of the two RAGE ligands between cases and controls. CONCLUSIONS: sRAGE is significantly lower in patients with COPD than in age- and sex-matched individuals without airflow obstruction. Emphysema and chronic cor pulmonale are independent predictors of reduced sRAGE in COPD. BioMed Central 2011 2011-03-30 /pmc/articles/PMC3072955/ /pubmed/21450080 http://dx.doi.org/10.1186/1465-9921-12-37 Text en Copyright ©2011 Miniati et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Miniati, Massimo
Monti, Simonetta
Basta, Giuseppina
Cocci, Franca
Fornai, Edo
Bottai, Matteo
Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study
title Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study
title_full Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study
title_fullStr Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study
title_full_unstemmed Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study
title_short Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study
title_sort soluble receptor for advanced glycation end products in copd: relationship with emphysema and chronic cor pulmonale: a case-control study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072955/
https://www.ncbi.nlm.nih.gov/pubmed/21450080
http://dx.doi.org/10.1186/1465-9921-12-37
work_keys_str_mv AT miniatimassimo solublereceptorforadvancedglycationendproductsincopdrelationshipwithemphysemaandchroniccorpulmonaleacasecontrolstudy
AT montisimonetta solublereceptorforadvancedglycationendproductsincopdrelationshipwithemphysemaandchroniccorpulmonaleacasecontrolstudy
AT bastagiuseppina solublereceptorforadvancedglycationendproductsincopdrelationshipwithemphysemaandchroniccorpulmonaleacasecontrolstudy
AT coccifranca solublereceptorforadvancedglycationendproductsincopdrelationshipwithemphysemaandchroniccorpulmonaleacasecontrolstudy
AT fornaiedo solublereceptorforadvancedglycationendproductsincopdrelationshipwithemphysemaandchroniccorpulmonaleacasecontrolstudy
AT bottaimatteo solublereceptorforadvancedglycationendproductsincopdrelationshipwithemphysemaandchroniccorpulmonaleacasecontrolstudy